Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Rituximab 18Cyclophosphamide 18Prednisone 12Doxorubicin 12Vincristine 9Lenalidomide 7ibrutinib 6obinutuzumab 5glofitamab 5Magnetic Resonance Spectroscopy 5polatuzumab vedotin 4fludarabine 4Prednisolone 4Oxaliplatin 4Gemcitabine 4Etoposide 4Cyclosporine 4venetoclax 3pembrolizumab 3fludarabine phosphate 3Whole-Body Irradiation 3Specimen Handling 3R-CHOP protocol 3Mycophenolic Acid 3Biopsy 3zanubrutinib 2prednylidene 2deltacortene 2acalabrutinib 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Spinal Puncture × 30 days × Clear all
NCT03984448 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
363 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡